Description
Primary hypercholesterolemia: It is indicated as a treatment added to the diet to reduce high concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides and cholesterol of lipoproteins other than those of high-density (non-HDL-C) and to increase high-density lipoprotein (HDL-C) cholesterol in adult and adolescent patients (10 to 17 yehttps://alphapharmaltd.org/wp-admin/post.php?post=4577&action=editars of age) with primary hypercholesterolaemia (heterozygous familial and non-familial) or with mixed hyperlipidemia.
Fenofibrate can be added to treatment in adult patients with mixed hyperlipidemia who require a greater reduction in triglycerides (TG) and non-HDL-C, as well as an increase in CHDL.
Homozygous familial hypercholesterolemia: It is indicated to decrease elevated levels of total cholesterol and LDL-C in adult and adolescent patients (10 to 17 years of age) with homozygous familial hypercholesterolemia, who may also receive adjunctive treatments (for example, LDL -aphaeresis).






Reviews
There are no reviews yet.